SCHEMBL22930104

SCHEMBL22930104

CCCCCCCC(CCCCCC)CCc1ccc(Br)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.47
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ ESR1 P03372 2/20 0.43
▸ ADRA2A P08913 2/20 0.43
▸ ADORA3 P0DMS8 2/20 0.43
▸ TACR2 P21452 2/20 0.43
▸ SLC6A2 P23975 2/20 0.43
▸ SLC6A4 P31645 2/20 0.43
▸ SLC6A3 Q01959 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ SHBG P04278 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ HSPD1 P10809 1/20 0.43
▸ ADRB3 P13945 1/20 0.43
▸ HTR2C P28335 1/20 0.43
▸ HSPE1 P61604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19350979 1.00 LMNA (0.47) LMNACYP1A2CYP2D6CYP2C19ESR1
SCHEMBL22930106 0.93 LMNA (0.47) LMNACYP1A2CYP2D6CYP2C19ESR1
SCHEMBL13470664 0.86 CYP1A2 (0.41) LMNACYP1A2CYP2D6CYP2C19ALDH1A1
SCHEMBL18070687 0.84 LMNA (0.46) LMNACYP1A2CYP2D6CYP2C19ESR1
SCHEMBL22930103 0.84 LMNA (0.49) LMNACYP1A2CYP2D6CYP2C19ESR1
SCHEMBL22930105 0.84 LMNA (0.49) LMNACYP1A2CYP2D6CYP2C19ESR1
SCHEMBL23577072 0.82 ESR1 (0.67) LMNAESR1ADRA2AADORA3TACR2
SCHEMBL982852 0.82 ESR1 (0.67) LMNAESR1ADRA2AADORA3TACR2
SCHEMBL982302 0.82 ESR1 (0.67) LMNAESR1ADRA2AADORA3TACR2
SCHEMBL980347 0.82 ESR1 (0.67) LMNAESR1ADRA2AADORA3TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10905769-B2 Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2021-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10905769-B2 Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use PLK1, POLR1E, POLK LMNA 3095/4885CYP1A2 4883/4885CYP2D6 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback